methyltransferase like 15 pseudogene 3Genealiases: []
Q-omics provides the consensus-scored METTL15P3 profile across patient tissues and cancer cell-line models. METTL15P3 expression is associated with patient survival in 18 of 34 cancer types, with the highest sampling consensus in READ. Among the 18 cancer types available for tumor–normal comparison, METTL15P3 is differentially expressed in 4, with the highest sampling consensus in KIRC. Additionally, METTL15P3 RNA expression shows 8,860 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight READ, KIRC, and THYM as cancer lineages where METTL15P3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for METTL15P3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes METTL15P3 survival associations across molecular data types. METTL15P3 RNA expression shows survival associations in the most cancer types (18). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible METTL15P3 RNA expression–survival associations across cancer types. High METTL15P3 expression shows unfavorable associations in READ, STAD, LIHC, LGG and CHOL, but favorable associations in KIRC. The READ Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify READ as the clearest survival context for METTL15P3 RNA expression.
This table summarizes METTL15P3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 4. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for METTL15P3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. METTL15P3 shows lower tumor expression in KIRC and higher tumor expression in KICH, LUSC and HNSC. The KIRC box plot shows higher METTL15P3 RNA expression in normal versus tumor tissue (log2 FC = −0.029, t-test p < 0.001).
This table shows molecular features associated with METTL15P3 in patient tissues and cancer cell lines. In patient samples, METTL15P3 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set.
